aztreonam has been researched along with Klebsiella Infections in 41 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Klebsiella Infections: Infections with bacteria of the genus KLEBSIELLA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "10 patients with meningitis due to unusual gram-negative organisms (Pseudomonas, Proteus, Salmonella and Klebsiella) were effectively treated with aztreonam." | 7.68 | Aztreonam for treating meningitis caused by gram-negative rods. ( Bishay, E; Farid, Z; Girgis, N; Kilpatrick, M, 1991) |
| "10 patients with meningitis due to unusual gram-negative organisms (Pseudomonas, Proteus, Salmonella and Klebsiella) were effectively treated with aztreonam." | 3.68 | Aztreonam for treating meningitis caused by gram-negative rods. ( Bishay, E; Farid, Z; Girgis, N; Kilpatrick, M, 1991) |
| " Dose-response relationships between antibiotic exposure and extended-spectrum-beta-lactamase-producing or AmpC-producing isolates were not demonstrated." | 1.43 | Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients. ( Adler, AL; Elward, A; Haaland, W; Kronman, MP; Miles-Jay, A; Newland, JG; Qin, X; Weissman, SJ; Zaoutis, T; Zerr, DM; Zhou, C, 2016) |
| " A humanized aztreonam dose of 2 g every 6 h (1-h infusion) was evaluated alone and in combination with avibactam at 375 or 600 mg every 6 h (1-h infusion), targeting the percentage of the dosing interval in which free-drug concentrations remained above the MIC (fT>MIC)." | 1.39 | Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. ( Crandon, JL; Nicolau, DP, 2013) |
| "A total of 143 patients with nosocomial infections due to K." | 1.33 | Nosocomial infection with cephalosporin-resistant Klebsiella pneumoniae is not associated with increased mortality. ( Gomes, CC; Levin, AS; Santos, CR; Vormittag, E, 2006) |
| "In addition, combined treatments of bacterial infections should allow for a reduction in dosages of antibiotics while at the same time, achieving increased efficacy." | 1.28 | Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections. ( Bizzini, B; Fattal-German, M, 1989) |
| "When chloramphenicol was added before the beta-lactams, the action of cefotaxime, moxalactam, or cefoperazone against all isolates was antagonized at all times tested." | 1.27 | Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae. ( Alford, RH; Brown, TH, 1984) |
| "Aztreonam is a novel antimicrobial agent belonging to the monobactam class of antibiotics." | 1.27 | Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.32) | 18.7374 |
| 1990's | 10 (24.39) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 10 (24.39) | 24.3611 |
| 2020's | 11 (26.83) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, W | 1 |
| Luo, Q | 1 |
| Shen, P | 1 |
| Chen, Y | 1 |
| Xu, H | 1 |
| Xiao, Y | 1 |
| Qiu, Y | 1 |
| Jalil, MB | 1 |
| Al Atbee, MYN | 1 |
| Xu, C | 1 |
| Wei, X | 1 |
| Jin, Y | 1 |
| Bai, F | 1 |
| Cheng, Z | 1 |
| Chen, S | 1 |
| Pan, X | 1 |
| Wu, W | 1 |
| Isler, B | 1 |
| Aslan, AT | 1 |
| Akova, M | 1 |
| Harris, P | 1 |
| Paterson, DL | 1 |
| Tiseo, G | 1 |
| Suardi, LR | 1 |
| Leonildi, A | 1 |
| Giordano, C | 1 |
| Barnini, S | 1 |
| Falcone, M | 1 |
| Mura, M | 1 |
| Longo, B | 1 |
| Andreini, R | 1 |
| Sbrana, F | 1 |
| Ripoli, A | 1 |
| Andreoli, E | 1 |
| Sani, S | 1 |
| Tumbarello, M | 1 |
| Meini, S | 1 |
| Sieswerda, E | 1 |
| van den Brand, M | 1 |
| van den Berg, RB | 1 |
| Sträter, J | 1 |
| Schouls, L | 1 |
| van Dijk, K | 1 |
| Budding, AE | 1 |
| Yasmin, M | 1 |
| Fouts, DE | 1 |
| Jacobs, MR | 1 |
| Haydar, H | 1 |
| Marshall, SH | 1 |
| White, R | 1 |
| D'Souza, R | 1 |
| Lodise, TP | 1 |
| Rhoads, DD | 1 |
| Hujer, AM | 1 |
| Rojas, LJ | 1 |
| Hoyen, C | 1 |
| Perez, F | 1 |
| Edwards, A | 1 |
| Bonomo, RA | 2 |
| Noel, AR | 1 |
| Attwood, M | 1 |
| Bowker, KE | 1 |
| MacGowan, AP | 1 |
| Camilleri, E | 1 |
| Maggini, N | 1 |
| Piccica, M | 1 |
| Botta, A | 1 |
| Poli, D | 1 |
| Bocanegra-Ibarias, P | 1 |
| Camacho-Ortiz, A | 1 |
| Garza-González, E | 1 |
| Flores-Treviño, S | 1 |
| Kim, H | 1 |
| Perez-Alba, E | 1 |
| Monogue, ML | 1 |
| Abbo, LM | 1 |
| Rosa, R | 1 |
| Camargo, JF | 1 |
| Martinez, O | 1 |
| Nicolau, DP | 2 |
| Jayol, A | 1 |
| Nordmann, P | 1 |
| Poirel, L | 1 |
| Dubois, V | 1 |
| Shaw, E | 1 |
| Rombauts, A | 1 |
| Tubau, F | 1 |
| Padullés, A | 1 |
| Càmara, J | 1 |
| Lozano, T | 1 |
| Cobo-Sacristán, S | 1 |
| Sabe, N | 1 |
| Grau, I | 1 |
| Rigo-Bonnin, R | 1 |
| Dominguez, MA | 1 |
| Carratalà, J | 1 |
| Chiu, SK | 1 |
| Ma, L | 1 |
| Chan, MC | 1 |
| Lin, YT | 1 |
| Fung, CP | 1 |
| Wu, TL | 1 |
| Chuang, YC | 1 |
| Lu, PL | 1 |
| Wang, JT | 1 |
| Lin, JC | 1 |
| Yeh, KM | 1 |
| Mittal, J | 1 |
| Szymczak, WA | 1 |
| Guo, Y | 1 |
| Levi, MH | 1 |
| Chen, L | 1 |
| Kreiswirth, BN | 1 |
| Riska, PF | 1 |
| Nori, P | 1 |
| Crandon, JL | 1 |
| McWilliams, CS | 1 |
| Condon, S | 1 |
| Schwartz, RM | 1 |
| Ginocchio, CC | 1 |
| Chen, YT | 1 |
| Siu, LK | 1 |
| Tsai, YK | 1 |
| Lin, FM | 1 |
| Koh, TH | 1 |
| Chen, JH | 1 |
| Zerr, DM | 1 |
| Miles-Jay, A | 1 |
| Kronman, MP | 1 |
| Zhou, C | 1 |
| Adler, AL | 1 |
| Haaland, W | 1 |
| Weissman, SJ | 1 |
| Elward, A | 1 |
| Newland, JG | 1 |
| Zaoutis, T | 1 |
| Qin, X | 1 |
| Marcano, D | 1 |
| Pasterán, F | 1 |
| Rapoport, M | 1 |
| Faccone, D | 1 |
| Ugarte, C | 1 |
| Salgado, N | 1 |
| Payares, D | 1 |
| Spadola, E | 1 |
| López, Y | 1 |
| Maggi, G | 1 |
| Galas, M | 1 |
| Sánchez, D | 1 |
| Piekarska, K | 1 |
| Zacharczuk, K | 1 |
| Szych, J | 1 |
| Zawidzka, E | 1 |
| Wilk, E | 1 |
| Wardak, S | 1 |
| Jagielski, M | 1 |
| Gierczyński, R | 1 |
| Nijssen, S | 1 |
| Florijn, A | 1 |
| Bonten, MJ | 1 |
| Schmitz, FJ | 1 |
| Verhoef, J | 1 |
| Fluit, AC | 1 |
| Gomes, CC | 1 |
| Vormittag, E | 1 |
| Santos, CR | 1 |
| Levin, AS | 1 |
| Panagiotakopoulou, A | 1 |
| Daikos, GL | 1 |
| Miriagou, V | 1 |
| Loli, A | 1 |
| Tzelepi, E | 2 |
| Tzouvelekis, LS | 2 |
| Brown, TH | 1 |
| Alford, RH | 1 |
| Arlet, G | 2 |
| Rouveau, M | 2 |
| Fournier, G | 1 |
| Lagrange, PH | 2 |
| Philippon, A | 2 |
| Legakis, NJ | 1 |
| Hatzoudis, G | 1 |
| Gourkou, A | 1 |
| Pitt, TL | 1 |
| Vatopoulos, AC | 1 |
| Hobson, RP | 1 |
| MacKenzie, FM | 1 |
| Gould, IM | 1 |
| Cantón, R | 1 |
| Morosini, MI | 1 |
| Ballestero, S | 1 |
| Alvarez, ME | 1 |
| Escobar, H | 1 |
| Máiz, L | 1 |
| Baquero, F | 1 |
| Blahová, J | 2 |
| Králiková, K | 2 |
| Krcméry, V | 2 |
| Torsová, V | 1 |
| Moland, ES | 1 |
| Sanders, CC | 1 |
| Thomson, KS | 1 |
| Hupková, M | 1 |
| Lísková, A | 1 |
| Kubonová, K | 1 |
| Shehabi, AA | 1 |
| Mahafzah, A | 1 |
| Baadran, I | 1 |
| Qadar, FA | 1 |
| Dajani, N | 1 |
| Nadjar, D | 1 |
| Verdet, C | 1 |
| Donay, L | 1 |
| Herrmann, J | 1 |
| Jeong, SH | 1 |
| Kim, WM | 1 |
| Chang, CL | 1 |
| Kim, JM | 1 |
| Lee, K | 1 |
| Chong, Y | 1 |
| Hwang, HY | 1 |
| Baek, YW | 1 |
| Chung, HK | 1 |
| Woo, IG | 1 |
| Ku, JY | 1 |
| Fayed, DF | 1 |
| Dahmash, NS | 1 |
| Saddique, AA | 1 |
| Shibl, AM | 1 |
| Kilpatrick, M | 1 |
| Girgis, N | 1 |
| Farid, Z | 1 |
| Bishay, E | 1 |
| van Ogtrop, ML | 1 |
| Mattie, H | 1 |
| Guiot, HF | 1 |
| van Strijen, E | 1 |
| Sekh, BR | 1 |
| van Furth, R | 1 |
| Bizzini, B | 1 |
| Fattal-German, M | 1 |
| Scully, BE | 1 |
| Neu, HC | 1 |
1 review available for aztreonam and Klebsiella Infections
| Article | Year |
|---|---|
Treatment strategies for OXA-48-like and NDM producing
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Carbape | 2022 |
1 trial available for aztreonam and Klebsiella Infections
| Article | Year |
|---|---|
Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aztreonam; Bacteremia; Citrobacter; Cross Infection; | 1992 |
39 other studies available for aztreonam and Klebsiella Infections
| Article | Year |
|---|---|
New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacteremia; beta-Lactamase Inhibitors; Boron | 2021 |
The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections.
Topics: Ampicillin; Anti-Bacterial Agents; Aztreonam; Cefepime; Ceftazidime; Ceftriaxone; Ciprofloxacin; Dru | 2022 |
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lac | 2022 |
Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae infections.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Drug Combinations; Humans; Klebsiella Infections; | 2023 |
Clinical outcomes in elderly patients with infections caused by NDM-producing Klebsiella pneumoniae: results from a real-life retrospective single center study in an endemic area.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Female; Humans; Klebsiella Infections; Klebsiella pne | 2023 |
Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Drug Combinati | 2020 |
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacteremia; Bacterial Proteins; beta-Lactama | 2020 |
Pharmacodynamics of aztreonam against Escherichia coli and Klebsiella oxytoca: defining pharmacodynamic targets.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Escherichia coli; Humans; Klebsiella; Klebsiella | 2020 |
A rare case of prothrombin time prolongation.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Aztreonam; Bacteremia; Blood Coagulation Disorders; Carc | 2021 |
Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacteremia; beta-Lactamases; Ceftazidime; Dr | 2020 |
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Ceftazid | 2017 |
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Carbapenem-Resist | 2018 |
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactam Resista | 2018 |
Carbapenem Nonsusceptible Klebsiella pneumoniae in Taiwan: Dissemination and Increasing Resistance of Carbapenemase Producers During 2012-2015.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; DNA, Bacterial; Drug Resistan | 2018 |
Two for the price of one: emerging carbapenemases in a returning traveller to New York City.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Ceftazidim | 2018 |
Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases | 2013 |
Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia col | 2014 |
A Common Flanking Region in Promiscuous Plasmids Encoding blaNDM-1 in Klebsiella pneumoniae Isolated in Singapore.
Topics: Anti-Bacterial Agents; Aztreonam; Base Sequence; beta-Lactamases; Ciprofloxacin; Conjugation, Geneti | 2016 |
Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; | 2016 |
First isolation of a VIM-producing Klebsiella pneumoniae from a seven-year-old child in Venezuela.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; | 2008 |
[Dissemination of the KPC carbapenemase producing Klebsiella pneumoniae in a hospital in Warsaw, Poland].
Topics: Adult; Aged; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; | 2010 |
Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalo | 2004 |
Nosocomial infection with cephalosporin-resistant Klebsiella pneumoniae is not associated with increased mortality.
Topics: Aztreonam; Brazil; Cephalosporin Resistance; Cross Infection; Drug Resistance, Bacterial; Female; Hu | 2006 |
Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Greece; | 2007 |
Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Chloramphenicol; Humans; Imipenem; Klebsiella Infe | 1984 |
Novel, plasmid-encoded, TEM-derived extended-spectrum beta-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; DNA Pr | 1993 |
Klebsiella pneumoniae infections in Greek hospitals. Dissemination of plasmids encoding an SHV-5 type beta-lactamase.
Topics: Aztreonam; Bacteriophage Typing; beta-Lactamases; Ceftazidime; Cephalosporins; DNA, Bacterial; Drug | 1995 |
An outbreak of multiply-resistant Klebsiella pneumoniae in the Grampian region of Scotland.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Cefotaxime; Ceftazidime; Cefuroxime; Cephal | 1996 |
Lung colonization with Enterobacteriaceae producing extended-spectrum beta-lactamases in cystic fibrosis patients.
Topics: Adolescent; Aztreonam; beta-Lactamases; Ceftazidime; Cystic Fibrosis; Drug Resistance, Microbial; Es | 1997 |
Transfer of antibiotic resistance and production of extended-spectrum beta-lactamase (ESBL) in nosocomial Klebsiella pneumoniae strains from two hospitals in Czech Republic.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistanc | 1997 |
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Escher | 1998 |
Transfer of resistance to oxy-imino-cephalosporins and of extended-spectrum beta-lactamase productions in Klebsiella pneumoniae strains from infected neonates.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistanc | 1998 |
High incidence of Klebsiella pneumoniae clinical isolates to extended-spectrum B-lactam drugs in intensive care units.
Topics: Aztreonam; beta-Lactam Resistance; Cefotaxime; Ceftazidime; Ceftriaxone; Cross Infection; Gram-Negat | 2000 |
Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei.
Topics: Amino Acid Sequence; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Cefepime; Cefota | 2000 |
Neonatal intensive care unit outbreak caused by a strain of Klebsiella oxytoca resistant to aztreonam due to overproduction of chromosomal beta-lactamase.
Topics: Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ceftriaxone; Cross Infection | 2001 |
Aztreonam for treating meningitis caused by gram-negative rods.
Topics: Adult; Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gram-Negative Bacteria; Hum | 1991 |
Comparison of the effects of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.
Topics: Animals; Aztreonam; Cells, Cultured; Chromatography, High Pressure Liquid; Dose-Response Relationshi | 1991 |
Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections.
Topics: Adjuvants, Immunologic; Ampicillin; Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; | 1989 |
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infectio | 1985 |